Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162500
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sokke Umeshappa, Channakeshava | - |
dc.contributor.author | Singha, Santiswarup | - |
dc.contributor.author | López Blanco, José Manuel | - |
dc.contributor.author | Shao, Kun | - |
dc.contributor.author | Hebbandi Nanjundappa1, Roopa | - |
dc.contributor.author | Yamanouchi, Jun | - |
dc.contributor.author | Parés Darnaculleta, Albert | - |
dc.contributor.author | Serra, Pau | - |
dc.contributor.author | Yang, Yang | - |
dc.contributor.author | Santamaria, Pere | - |
dc.date.accessioned | 2020-05-26T16:50:16Z | - |
dc.date.available | 2020-05-26T16:50:16Z | - |
dc.date.issued | 2019-05-14 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | http://hdl.handle.net/2445/162500 | - |
dc.description.abstract | Peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines displaying tissue-specific autoantigenic epitopes can blunt specific autoimmune conditions by re-programming cognate antigen-experienced CD4+ T-cells into disease-suppressing T-regulatory type 1 (TR1) cells. Here, we show that single pMHCII-based nanomedicines displaying epitopes from mitochondrial, endoplasmic reticulum or cytoplasmic antigens associated with primary biliary cholangitis (PBC) or autoimmune hepatitis (AIH) can broadly blunt PBC, AIH and Primary Sclerosing Cholangitis in various murine models in an organ- rather than disease-specific manner, without suppressing general or local immunity against infection or metastatic tumors. Therapeutic activity is associated with cognate TR1 cell formation and expansion, TR1 cell recruitment to the liver and draining lymph nodes, local B-regulatory cell formation and profound suppression of the pro-inflammatory capacity of liver and liver-proximal myeloid dendritic cells and Kupffer cells. Thus, autoreactivity against liver-enriched autoantigens in liver autoimmunity is not disease-specific and can be harnessed to treat various liver autoimmune diseases broadly. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41467-019-09893-5 | - |
dc.relation.ispartof | Nature Communications, 2019, vol. 10, p. 2150 | - |
dc.relation.uri | https://doi.org/10.1038/s41467-019-09893-5 | - |
dc.rights | cc-by (c) Sokke Umeshappa, Channakeshava et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Pèptids | - |
dc.subject.classification | Malalties autoimmunitàries | - |
dc.subject.classification | Cèl·lules T | - |
dc.subject.classification | Hepatitis | - |
dc.subject.other | Peptides | - |
dc.subject.other | Autoimmune diseases | - |
dc.subject.other | T cells | - |
dc.subject.other | Hepatitis | - |
dc.title | Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 694854 | - |
dc.date.updated | 2020-05-26T16:50:18Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31089130 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
694854.pdf | 2.08 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License